Inclusion criteria
prostate cancer
DISEASE, RECURRENCE, PROSTATE CANCER, METASTATIC DISEASE

Men aged ≥ 18 with histologically confirmed prostate cancer after prostatectomy with detectable PSA. Patients with detectable post-prostatectomy PSA whether (1) persistently detectable post-operatively or (2) developing biochemical recurrence after prostatectomy (initially undetectable) are eligible. Patients with early BCR or persistently detectable PSA after prostatectomy must wait a minimum of 6 months post-prostatectomy but can initiate ADT as indicated. PSA does not need to be detectable for men with pathologically node positive disease.KPS ≥ 70Patient with no evidence of distant metastatic disease on positron emission tomography (PET)/CT/MRI or bone scan < 90–180 days prior to enrollment. Patients with positive pelvic lymph nodes are eligible.Ability to receive MRI-guided radiotherapyEquivocal evidence of metastatic disease outside the pelvis on standard imaging requires documented negative biopsyAbility to complete the EPIC questionnaire